Innovotech Inc. Reports Record Revenue For Its Third Quarter.

(TheNewswire)

Edmonton, Alberta, November 4, 2025– TheNewswire - Innovotech Inc. (TSX-V: IOT)(“Innovotech” or the “Company”) generated record revenues inQ3-2025 ($1,267,692) including a net income of $92,945.  On ayear-to-date basis, the Company has generated $3,410,204 in revenues. Several contributing factors drive revenues, including growingdemand for antimicrobial contract research services, strongperformance from analytical services, represented by the wholly-ownedsubsidiary Keystone Labs, and an increase in product sales.

“The Company has been building a foundation forcontinued growth and making multiple parallel efforts and investmentsto support expansion,” said Craig Milne, CEO. ”We are pleased tosee the financial performance reflecting the changesunderway.”

About Innovotech:

Innovotech Inc. is a diversified Canadian technologycompany with business operations in a growing portfolio of specializedlaboratory services, biotechnology businesses, and proprietaryintellectual property. Innovotech Inc. manages several subsidiarycompanies.  Innovotech Labs Corporation is a contract researchorganization that owns and provides proprietary devices forantimicrobial testing in multiple applications and commercializesantimicrobial silver solutions. Learn more at www.innovotech.ca . Keystone Labs Inc. is a DEL-accredited lab serving theCanadian pharmaceutical industry and industrial markets. Learn more at www.keystonelabs.ca. InnovotechInc. owns a 60% stake in NouLifeSciences Inc., a company holdingintellectual property related to antioxidant molecules with potentialapplications in cosmetics and various medical conditions includingneuropathies.

Craig Milne, CEO Innovotech Inc.

+1-604-239-1819        craig.milne@innovotech.ca

This document may containforward-looking statements that are predictive in nature and subjectto risks and uncertainties that cannot be predicted or quantified;consequently, actual results may differ materially from past resultsand those expressed or implied by any forward-looking statements.Factors that could cause or contribute to such risks or uncertaintiesinclude, but are not limited to: the regulatory environment includingthe difficulty of predicting regulatory outcomes; changes in the valueof the Canadian dollar; the Company’s reliance on a small number ofcustomers including government organizations; fluctuations inoperating results; government policies or actions; progress and costof clinical trials; reliance on key strategic relationships;uncertainty related to intellectual property protection and potentialcosts associated with its defense; the Company’s exposure tolawsuits and other matters beyond the control of management. Shouldknown or unknown risks or uncertainties materialize, or shouldmanagement’s assumptions prove inaccurate, actual results could varymaterially from those anticipated. The Company undertakes no obligation to publicly makeor update any forward- looking statements, except as required byapplicable law.

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this release.

###

Copyright (c) 2025 TheNewswire - All rights reserved.